Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Scientists test sits at the center of this dementia and brain health question.
Yes, scientists are testing several promising new methods for slowing the progression of serious diseases, and the results so far have been encouraging. From gene therapy approaches that have slowed Huntington’s disease by 75 percent to stem cell implants being tested for Parkinson’s disease, researchers are moving beyond symptom management toward actually slowing how diseases advance in the body. For people living with progressive neurological conditions, this shift represents a fundamental change in what treatment means.
These new approaches work through different mechanisms depending on the disease. Some use the body’s own immune system to clear harmful protein buildup, others replace damaged cells with healthy lab-grown versions, and still others target the genetic roots of disease itself. While not every experimental treatment will become available or effective for all patients, the variety of approaches being tested suggests we’re in an era where disease progression may be slowed in ways previously thought impossible.
Table of Contents
- What Are the Major New Methods Scientists Are Testing?
- How Do These Methods Actually Slow Disease Progression?
- What Diseases Are Being Tested for Progression-Slowing Treatments?
- How Do These New Approaches Compare to Traditional Treatments?
- What Are the Limitations and Risks of These New Methods?
- How Might These Treatments Work Together with Current Care?
- What Does the Future Look Like for Disease-Slowing Research?
- Conclusion
What Are the Major New Methods Scientists Are Testing?
The emerging approaches fall into several categories. Gene therapy, where scientists modify or introduce genetic material to slow disease, has shown dramatic results. An experimental gene therapy called AMT-130 slowed Huntington’s disease progression by 75 percent over 36 months in trial participants, helping them maintain their ability to move, think, and carry out daily activities. This represents one of the most significant advances in Huntington’s treatment in decades, offering hope to families who previously had limited options. Stem cell therapy represents another major approach. At Keck Medicine of USC, researchers are testing implants of lab-grown dopamine-producing cells directly into the brain’s movement-control region in Parkinson’s disease patients.
The goal is to replace neurons that have died or stopped functioning, potentially restoring motor control and slowing disease progression. This approach is still in testing phases, but early results suggest it may help patients maintain function longer than current medications alone. A third category involves better understanding how existing drugs work and optimizing their use. Researchers recently discovered that the Alzheimer’s drug lecanemab (marketed as Leqembi) works by activating the brain’s immune cells through a mechanism called the Fc fragment. These activated immune cells, called microglia, then clear away the amyloid plaques that damage brain cells and cause cognitive decline. Understanding the mechanism makes it possible to potentially improve similar treatments or develop related therapies.
How Do These Methods Actually Slow Disease Progression?
The key difference between slowing disease and treating symptoms is fundamental. Most traditional medications for progressive diseases work like a car’s air freshener—they mask the problem temporarily but don’t address the underlying damage. Slowing disease progression means interrupting or reversing the actual biological processes that cause cells to deteriorate. In the case of Huntington’s disease and the AMT-130 gene therapy, scientists are targeting the huntingtin protein that accumulates and damages cells. By reducing the amount of this harmful protein, the therapy helps prevent the cascade of cellular damage that characterizes the disease.
In Alzheimer’s disease, slowing progression through lecanemab works by preventing or reducing the amyloid plaques that contribute to neuroinflammation and cell death. However, it’s important to note that lecanemab works best in early stages of cognitive decline—once significant brain damage has occurred, the drug has less ability to help. This limitation highlights why early diagnosis is crucial for newer disease-modifying treatments. For stem cell therapies like those being tested for Parkinson’s disease, the mechanism is more straightforward: replacing cells that have died or stopped producing dopamine. The challenge here is ensuring the implanted cells survive long-term in the recipient’s brain and properly integrate with existing neural networks. Early results are promising, but patients should understand this remains an experimental procedure with unknown long-term outcomes.
What Diseases Are Being Tested for Progression-Slowing Treatments?
Beyond Huntington’s and Parkinson’s, multiple serious conditions are receiving attention. Type 1 diabetes researchers are testing AIDANET, an AI-monitored therapy being used at home in over 50 people. Rather than slowing a progressive degenerative disease, this approach aims to help the immune system better manage blood sugar and reduce the complications that accumulate over time. Results from this trial are expected soon and could prove that AI-supported therapies can work in a home setting, not just in research hospitals. ALS (amyotrophic lateral sclerosis) is another area of intense research.
A global clinical trial called PREVAiLS is currently enrolling 500 participants to test whether a drug called pridopidine can slow disease progression in early and rapidly progressive ALS patients. ALS typically progresses quickly—patients often lose motor function within 2-5 years of diagnosis—so a treatment that even modestly slows this timeline would be significant for quality of life and survival. Osteoarthritis is also getting attention, though in a different way. Rather than slowing a degenerative disease, researchers supported by ARPA-H (Advanced Research Projects Agency for Health) are testing experimental treatments that could actually regrow cartilage and bone damaged by arthritis. If successful, these approaches would move beyond slowing joint damage to reversing it—a higher bar than many other disease-slowing therapies currently achieve.
How Do These New Approaches Compare to Traditional Treatments?
Traditional medications for progressive diseases typically manage symptoms for a period of time before patients develop tolerance or the disease advances beyond what the drug can address. Parkinson’s medications like levodopa work well initially but often become less effective over years as the disease progresses. The dopamine cell implants being tested represent a completely different approach—attempting to restore the biological system itself rather than artificially boosting a depleted chemical. The comparison is instructive: a patient on levodopa might maintain reasonable motor function for 5-10 years before requiring higher doses or additional medications. A patient receiving successful dopamine cell implants might theoretically maintain function longer and with fewer complications, though this remains to be proven in long-term studies.
The tradeoff is that stem cell implantation is a surgical procedure with its own risks, whereas taking a pill carries minimal procedural risk. This is why such treatments are typically offered to patients who have already failed other options or who are willing to accept surgical risk for the potential of longer-term benefit. Gene therapies like AMT-130 for Huntington’s disease represent a similar shift. Huntington’s has no disease-modifying treatment today—medications only manage symptoms like movement disorders or psychiatric problems. A treatment that slows progression by 75 percent would be transformative, even if it doesn’t stop the disease entirely. However, gene therapy carries the complexity of delivery (getting the therapy into the right brain cells) and potential immune responses, making it a more intensive intervention than current oral medications.
What Are the Limitations and Risks of These New Methods?
Every new treatment approach carries uncertainties and limitations. Gene therapies, while promising, are permanent—once administered, they cannot be easily reversed if side effects emerge. While AMT-130 has shown 75 percent slowing of Huntington’s progression, this still means some progression continues. Patients should understand that slowing is not the same as stopping, and the long-term effects beyond the 36-month trial period remain unknown. Stem cell therapies face the challenge of immune rejection, even when cells are derived from the patient’s own tissues. The implanted dopamine cells in the Parkinson’s trial may not survive indefinitely in the recipient’s brain, or they may integrate imperfectly with existing neural networks.
Additionally, these procedures are expensive and not yet covered by most insurance plans, making them accessible only to patients with substantial financial resources. This creates an equity problem in access to potentially life-changing treatments. For drugs like lecanemab in Alzheimer’s disease, there’s a critical window of opportunity. The drug works best in early cognitive decline but becomes less effective as more brain damage has accumulated. This means patients must be diagnosed early enough to benefit—a challenge given that many people don’t seek evaluation until symptoms are more obvious. Additionally, lecanemab carries a small risk of amyloid-related imaging abnormalities (ARIA), which can include brain microhemorrhages or microinfarcts. While serious complications are rare, patients taking the drug require regular MRI monitoring.
How Might These Treatments Work Together with Current Care?
In practice, disease-slowing treatments are likely to complement rather than replace current symptom management. A patient with Parkinson’s disease who receives dopamine cell implants might still benefit from levodopa for additional symptom management. A patient on lecanemab for Alzheimer’s disease would continue cognitive therapy, exercise programs, and other lifestyle modifications that support brain health.
This multimodal approach reflects current medical practice in other areas. Cancer patients, for example, often receive multiple treatments simultaneously—surgery, chemotherapy, and targeted therapies—each attacking the disease through different mechanisms. As disease-slowing treatments become available for neurological conditions, similar combination approaches are likely to emerge. The key is that new treatments are being added to the toolkit rather than replacing it entirely.
What Does the Future Look Like for Disease-Slowing Research?
The accelerating pace of breakthroughs suggests we’re entering a new era in how we approach progressive disease. Advances in understanding disease mechanisms—like the discovery of how lecanemab actually works—create opportunities for improved or related treatments. Similarly, successes with gene therapy for Huntington’s disease are inspiring similar approaches for other genetic conditions.
The shift toward home-based and outpatient treatments is also significant. The AIDANET trial for Type 1 diabetes and advances in delivering CAR-T cell cancer therapies at home or in outpatient clinics indicate that complex medical treatments don’t always require hospitalization. Over time, disease-slowing treatments may become accessible to more patients in more settings. However, these advances will likely remain expensive and require sophisticated monitoring for years to come, raising important questions about equity and access.
Conclusion
Scientists are indeed testing new methods for slowing disease progression across multiple serious conditions, from Huntington’s disease to Parkinson’s to Alzheimer’s disease. These approaches—gene therapy, stem cell implants, immune system activation, and AI-supported therapies—represent a meaningful shift from simply managing symptoms toward actually slowing how diseases advance. The results to date have been encouraging, with some treatments showing substantial benefit in clinical trials.
For patients and families dealing with progressive disease, these advances offer genuine hope. However, it’s important to maintain realistic expectations: slowing disease progression is not the same as curing it, and these treatments often come with their own complexities, costs, and limitations. The next steps involve completing ongoing trials, understanding long-term outcomes, and making these treatments increasingly accessible to patients who could benefit from them.
You Might Also Like
- New Treatment Pathway Discovered for Alzheimer’s Disease
- New Study Reveals Structural Impact of Disease
- Researchers Investigate Biological Factors in Disease Development
For more, see Alzheimer’s Association — clinical trials.
